Client is a biopharmaceutical company that develops medicines in areas of unmet need.
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R.5378 - Lower Costs, More Transparency Act Issues related to commercial delinking of PBMs - H.R.6283/S.1542 - DRUG Act Access and reimbursement of drugs in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 H.R.5378 - Lower Costs, More Transparency Act Issues related to Part D delinking of PBMs, H.R.2880 - Protecting Patients Against PBM Abuses Act, S.1967 - PBM Act S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
HCR - Health Issues MMM - Medicare/Medicaid
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
THE MCMANUS GROUP
610 10th St. NW, Suite 300, Washington, DC, 20001, US
JOHN MCMANUS JOHN MCMANUS